








BMJ Open

Role of fatty liver in the epidemic of advanced chronic liver disease among people with HIV: protocol for the Canadian LIVEHIV multicentre prospective cohort

Felice Cinque ^{1,2}, Sahar Saeed,³ Dana Kablawi,^{1,2} Luz Ramos Ballesteros,^{1,2}
Wesal Elgretli,⁴ Erica E M Moodie,⁵ Colleen Price,⁶ Ken Monteith,⁷
Curtis Cooper ⁸, Sharon L Walmsley,⁹ Neora Pick,¹⁰ Melanie C M Murray,¹⁰
Joseph Cox,^{1,5} Nadine Kronfli,¹ Cecilia T Costiniuk ¹¹,
Alexandra de Pokomandy ¹, Jean-Pierre Routy ¹, Bertrand Lebouché ^{1,12},
Marina B Klein,^{1,5} Giada Sebastiani ^{1,2,4,5}

To cite: Cinque F, Saeed S, Kablawi D, *et al.* Role of fatty liver in the epidemic of advanced chronic liver disease among people with HIV: protocol for the Canadian LIVEHIV multicentre prospective cohort. *BMJ Open* 2023;**13**:e076547. doi:10.1136/bmjopen-2023-076547

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2023-076547>).

FC and SS contributed equally.

FC and SS are joint first authors.

Received 09 June 2023
Accepted 08 August 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Giada Sebastiani;
giada.sebastiani@mcgill.ca

ABSTRACT

Introduction Advanced chronic liver disease (ACLD) is a major cause of death for people with HIV (PWH). While viral hepatitis coinfections are largely responsible for this trend, metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging concern for PWH. We aimed to assess the contribution of MASLD to incident ACLD in PWH.

Methods and analysis This multicentre prospective observational cohort study will enrol 968 consecutive HIV monoinfected patients from four Canadian sites, excluding subjects with alcohol abuse, liver disease other than MASLD, or ACLD at baseline. Participants will be followed annually for 4 years by clinical evaluation, questionnaires, laboratory testing and Fibroscan to measure liver stiffness measurement (LSM) and controlled attenuation parameter (CAP). The primary outcome will be incidence of ACLD, defined as $LSM > 10 \text{ kPa}$, by MASLD status, defined as $CAP \geq 285 \text{ dB/m}$ with at least one metabolic abnormality, and to develop a score to classify PWH according to their risk of ACLD. Secondary outcomes will include health-related quality of life (HRQoL) and healthcare resource usage. Kaplan-Meier survival method and Cox proportional hazards regression will calculate the incidence and predictors of ACLD, respectively. Propensity score methods and marginal structural models will account for time-varying exposures. We will split the cohort into a training set (to develop the risk score) and a validation set (for validation of the score). HRQoL scores and healthcare resource usage will be compared by MASLD status using generalised linear mixed effects model.

Ethics and dissemination This protocol has been approved by the ethics committees of all participating institutions. Written informed consent will be obtained from all study participants. The results of this study will be shared through scientific publications and public presentations to advocate for the inclusion of PWH in clinical trials of MASLD-targeted therapies and case-finding of ACLD in PWH.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This multicentre, prospective study will enrol a large number of consecutive people with HIV (PWH) mono-infection at four different Canadian sites.
- ⇒ By dividing the cohort into a training and validation set, we will be able to develop a clinically relevant risk score to stratify PWH according to increased risk of advanced chronic liver disease (ACLD).
- ⇒ Thanks to the significant involvement of community allies in the development of the protocol, the study will also focus on patient-centred outcomes and quality of life.
- ⇒ As liver biopsy is not feasible for a large cohort study, ACLD will be assessed by transient elastography, a well-validated, non-invasive, cost-effective diagnostic tool that will help broaden the generalisability of the study and reduce selection bias.
- ⇒ Despite being underpowered to tease out the effect of single antiretroviral therapy (ART) drugs, we will conduct sensitivity analyses to account for cumulative ART exposure and by class.

INTRODUCTION

With 62790 people affected in Canada and more than 38million worldwide, the HIV continues to be a major public health issue.^{1 2} Antiretroviral therapy (ART) has changed the prognosis of HIV infection, with a dramatic reduction in AIDS-related deaths.³ However, as people with HIV (PWH) age, the burden of non-AIDS related mortality rises.⁴ Liver disease is one of the leading causes of non-AIDS related mortality.^{5 6} The recently proposed term advanced chronic liver disease (ACLD) reflects the continuum of advanced liver fibrosis and cirrhosis, emphasising that

portal hypertension, responsible for the majority of end-stage liver complications, may occur before a formal anatomical diagnosis of liver cirrhosis.⁷ Liver fibrosis can be measured non-invasively using transient elastography by Fibroscan (Echosens, Paris, France), providing a safe and cost-effective identification of asymptomatic patients with ACLD at risk of developing hepatic decompensation and all-cause mortality.⁸ Although liver biopsy remains the gold standard, according to the Baveno consensus liver stiffness measurement (LSM) by transient elastography is sufficient to suspect ACLD.⁹ A variety of factors, including coinfection with hepatitis C (HCV) and hepatitis B (HBV) viruses, the high frequency of alcohol use, the hepatotoxicity of ART and metabolic dysfunction-associated steatotic liver disease (MASLD), contribute to ACLD in PWH.¹⁰ HCV infection remains the leading cause of liver-related death in PWH, but the availability of highly effective new direct-acting antivirals has dwarfed the mortality trend.¹¹ Conversely, MASLD-related deaths in PWH are worryingly increasing, paralleling the raising prevalence of metabolic syndrome and other aging-related conditions.¹¹ In June 2023, an international consensus panel introduced steatotic liver disease (SLD) as an umbrella term encompassing the various etiologies of hepatic steatosis.¹² MASLD, formerly known as non-alcoholic fatty liver disease, is defined as evidence of hepatic steatosis with at least one cardiometabolic risk factor, in the absence of excessive alcohol intake or other known causes of SLD.¹² It encompasses a range of conditions, from simple steatosis to metabolic dysfunction-associated steatohepatitis, eventually evolving to liver fibrosis and ACLD, ultimately leading to liver failure and hepatocellular carcinoma (HCC).^{13 14} Affecting approximately 30% of the world's population, MASLD is the most common liver disease globally and plays a central role in the epidemic of ACLD.¹⁵ MASLD is projected to become the leading indication for liver transplantation in North America in the next 10 years.¹⁶ Beyond liver disease, MASLD is emerging as a multisystem disease affecting extra-hepatic organs and a risk factor for all-cause mortality.¹⁷ Furthermore, patients with MASLD often experience a range of mental, emotional and social problems, resulting in impaired health-related quality of life (HRQoL).¹⁸ As a result, patients with MASLD consume large amounts of healthcare resources.¹⁹

MASLD is more common and severe in PWH compared with the general population.²⁰ Our cross-sectional data found a prevalence of MASLD up to 48%, while ACLD seems four times more prevalent than in the general population.^{21 22} These findings are consistent with a recent meta-analysis in PWH reporting a prevalence of MASLD on imaging studies at 34%, and a prevalence of biopsy-proven significant liver fibrosis at 23%.²³ This reflects the complex and multifaceted pathogenesis of MASLD in PWH, with highly prevalent classical metabolic risk factors and unique HIV determinants, such as immune activation, virus-induced direct effect, systemic chronic inflammation and life-long exposure to ART.²⁰ Therefore,

the European AIDS Clinical Society guidelines recommend the use of transient elastography or serum fibrosis biomarkers for case-finding of liver fibrosis and ACLD in PWH without viral hepatitis coinfection and with metabolic abnormalities, or elevation of liver transaminases or any exposure to dideoxynucleoside drugs (d-drugs) such as stavudine and didanosine.²⁴ Nevertheless, hepatological societies still do not acknowledge HIV infection as a high-risk condition for MASLD.²⁵ PWH are excluded from global clinical trials of MASLD-targeted therapies.²⁶ Thus, there is a need for further high-quality evidence on the role of MASLD in the epidemic of ACLD in PWH mono-infection. In addition, to better allocate healthcare resources, it is clinically relevant to identify patients at high risk for progression to ACLD and thus develop an ad hoc risk score, incorporating HIV-related features. Finally, little is known about the impact of MASLD on the HRQoL and the use of healthcare resources in PWH.

STUDY OBJECTIVES

Primary objectives

- To determine the risk of incident ACLD by MASLD status (presence/absence) and by MASLD severity as determined by LSM with controlled attenuation parameter (CAP) in PWH.
- To develop a risk score to classify PWH into increasing risk categories for development of ACLD based on identified predictors.

Secondary objectives

- To determine the effect of MASLD on HRQoL in PWH.
- To determine the effect of MASLD on healthcare resource usage in PWH.
- To establish a tissue bank of plasma and serum from 150 participants as a resource for future studies of MASLD, to better investigate correlations of additional known and unknown parameters with ACLD.

METHODS AND ANALYSIS

Study design

This study is a multicentre, prospective, observational cohort of PWH (LIVEr disease in HIV (LIVEHIV) Cohort study). Nine hundred and sixty-eight participants will be recruited from four sites in Canada including (1) the McGill University Health Centre (MUHC) (Montreal), (2) the Ottawa General Hospital, (3) the Toronto General Hospital and (4) the Oak Tree Clinic (Vancouver). These sites were selected because of the large number of diverse PWH they follow, the well-established research infrastructure with availability of LSM with CAP, and their history of successful enrolment in Canadian HIV Trials Network (CTN) studies.

Participants

Inclusion criteria

(1) Age >18 years old; (2) historical HIV seropositive (ELISA with Western blot confirmation); (3) able to provide informed consent, in French or English.

Exclusion criteria

(1) Presence of the outcome at baseline (ACLD); (2) liver decompensation; (3) contraindications to transient elastography (pregnancy or pacemaker); (4) unreliable LSM (interquartile range [IQR]>30%, less than 10 validated measures); (5) coinfection with HCV or HBV; (6) significant alcohol intake (Alcohol Use and Disorders Identification Test (AUDIT-C) score >4 in men and >3 in women²⁷); (7) autoimmune liver or cholestatic disease, haemochromatosis, Wilson disease, alpha-1-antitrypsin deficiency; (8) pregnancy.

All PWH meeting eligibility criteria will be approached for participation consecutively, independently of known risk factors for the primary exposure (MASLD) and outcome (ACLD).

Participant timeline

Participants will be followed on yearly basis after baseline visit for 4 years (table 1). Participants will undergo an initial evaluation (baseline) followed by visits every 12 months (± 2 months). In case of any complication during the course of study participation, such as liver decompensation, end-stage liver disease or $\text{LSM} \geq 15 \text{ kPa}$, the follow-up visit will be changed to twice a year for 4 years and patients will undergo surveillance for HCC according to each site's protocol for the management of patients with ACLD, consisting of ultrasound and serum alpha-fetoprotein, as well as consideration for esophagogastroduodenoscopy following the Baveno VII consensus criteria.^{9 27} HIV care providers will be notified of the finding of any complication occurred during study participation.

Outcome measures

Primary outcome

The primary outcome will be the development of ACLD, defined as $\text{LSM} > 10 \text{ kPa}$, confirmed by a second transient elastography 1 week later. The main exposure will be MASLD, defined according to the recent multi-society Delphi consensus statement, as the presence of hepatic steatosis, defined as $\text{CAP} > 285 \text{ dB/m}$, plus at least one out of five cardiometabolic criteria: (1) overweight or waist circumference $> 94 \text{ cm}$ for man and $> 80 \text{ cm}$ for women; (2) fasting serum glucose $\geq 5.6 \text{ mmol/L}$ or 2-hour post-load glucose levels $\geq 7.8 \text{ mmol/L}$ or haemoglobin glycosylated $\geq 5.7\%$ or type 2 diabetes or treatment for type 2 diabetes; (3) blood pressure $\geq 130/85 \text{ mm Hg}$ or specific antihypertensive drug treatment; (4) plasma triglycerides $\geq 1.70 \text{ mmol/L}$ or lipid lowering treatment; (5) plasma high-density lipoprotein-cholesterol $\leq 1.0 \text{ mmol/L}$ in men and $\leq 1.3 \text{ mmol/L}$ in women, or lipid lowering treatment and no other discernible causes of SLD.¹² Severe MASLD is defined as $\text{CAP} > 300 \text{ dB/m}$.²⁸

Secondary outcomes

► HRQoL assessed by patient-reported outcome measures: Short Form-36 (SF-36) and Chronic Liver Disease Questionnaire (CLDQ).

- Healthcare resource usage measured by self-reported questionnaires and linkage to provincial linked data.
- Development of end-stage liver disease and cardiovascular disease.

Sample size

We based the sample size calculation on a conservative prevalence of MASLD in PWH of 36.4% and our published rate of progression to significant liver fibrosis (stage 2) of 12.7 (95% CI 9.5 to 17.1) per 100 person-years (PY) over 4-year follow-up.^{22 29} We expect a conservative incidence rate of ACLD (stages 3 and 4) of 3.0 (95% CI 1.1 to 5.5) vs 1.2 per 100 PY (95% CI 0.4 to 3.1) in patients with and without MASLD, respectively. Thus, the overall event rate would be 11% and 5% for ACLD over 4 years in patients with vs without MASLD, respectively. We require a sample size of 880 with 4-year follow-up to achieve 80% power to detect a hazard ratio (HR) of 2.0 with a type I error rate of 5%. We will increase our sample size to 968 to account for 10% potential dropouts, loss to follow-up and Fibroscan failure or unreliable measurement (figure 1).

Recruitment

Patients will be informed about the study either during routine HIV clinic follow-up visits or during transient elastography visits, and through established recruitment strategies by our community partners and the CTN via websites, email and social media platforms. All PWH meeting the eligibility criteria will be approached for participation. To broaden generalisability, anyone who meets the eligibility criteria may participate in the study if they can come to the enrolment sites for the study visits. Potentially eligible candidates can be notified by following the instructions provided on the CTN website.³⁰ Participants will be compensated \$25 per study visit.

Clinical, instrumental and laboratory evaluations

Clinical evaluations

Once a participant has been identified for screening, the details of the study are carefully discussed with them. The participant will be asked to read and sign the approved informed consent form prior to any assessments being performed. Clinical assessment will include measurements of body mass index (BMI), waist circumference and hip circumference to calculate waist-to-hip ratio and blood pressure. Clinical charts will be reviewed to collect information about sociodemographic characteristics, medical history (comorbidities and concomitant medications), HIV-related variables (date of HIV diagnosis, date of initiation of ART, CD4 count nadir, history of ART), development of end-stage liver disease (oesophageal varices, hepatic encephalopathy, ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, HCC, liver transplantation or liver-related death) and development of cardiovascular disease (myocardial infarction, angina, stroke or peripheral arterial disease).

Table 1 Schedule of visits and procedures

| Procedures | Visit 1 | | Visit 2 | Visit 3 | Visit 4 | Visit 5 |
|---|--|----------|-------------------------|-------------------------|-------------------------|-------------------------|
| | Screening | Baseline | Follow-up (12±3 months) | Follow-up (24±3 months) | Follow-up (36±3 months) | Follow-up (48±3 months) |
| Assessment of eligibility | X | | | | | |
| Consent form | X | X | X | X | X | X |
| Fibroscan | | X | X | X | X | X |
| Confirmation of eligibility (includes Fibroscan result and AUDIT-C) | | X | | | | |
| Clinical assessment | | X | X | X | X | X |
| | <ul style="list-style-type: none"> ▶ Weight and height to calculate BMI ▶ Waist circumference ▶ Blood pressure ▶ Standard of care laboratory tests | | | | | |
| Biobanking | Plasma and serum sampling* | X | | | | |
| Questionnaires | <ul style="list-style-type: none"> ▶ Medical information questionnaire ▶ AUDIT-C ▶ FFQ-SF ▶ IPAQ-SF ▶ CLDQ and SF 36 (PROS-HRQoL) ▶ HATS questionnaire ▶ Health resource usage questionnaire | X | X | X | X | X |
| Report laboratory tests | <ul style="list-style-type: none"> ▶ Liver profile (ALT, AST, GGT, alkaline phosphatase, total bilirubin, albumin, coagulation profile) ▶ Complete blood count, biochemistry; fasting lipid profile, glucose and insulin fasting for at least 12 hours prior to bloodwork ▶ Autoimmune markers (AMA, ANA, anti-LKM, ASMA, immunoglobulins); serum ferritin and transferrin saturation ▶ Plasma HIV RNA; lymphocyte subsets (absolute and relative CD4, nadir CD4, CD8 T-cell counts) | X | X | X | X | X |
| | HAV, HBV and HCV serology (if not documented within 1 year of study entry) | X | | | | |
| In the case of ACLD | 6-monthly serum alpha-fetoprotein and ultrasound in patients who develop ACLD (Fibroscan>10 kPa) | | X | X | X | X |
| | Outcome measure form (end stage liver disease form) | | X | X | X | X |

Continued

Table 1 Continued

| Procedures | | Visit 1 | | Visit 2 | Visit 3 | Visit 4 | Visit 5 |
|--------------|---|-----------|----------|-------------------------|-------------------------|-------------------------|-------------------------|
| | | Screening | Baseline | Follow-up (12±3 months) | Follow-up (24±3 months) | Follow-up (36±3 months) | Follow-up (48±3 months) |
| Chart review | <ul style="list-style-type: none"> ▶ Medical history: report hepatic and HIV-related diagnoses ▶ Antiretroviral history; report past and current ART ▶ Concomitant medications; report ongoing medications | X | X | X | X | X | X |

*Substudy for 150 participants consent to banking plasma and serum samples for the McGill University Health Centre only. anti-LKM; anti-liver/kidney microsomal antibodies; ACLD, advanced chronic liver disease; ALT, alanine aminotransferase; AMA, antimitochondrial antibody; ANA, antinuclear antibody; ART, antiretroviral therapy; ASMA, anti-smooth muscle antibody; AST, aspartate aminotransferase; AUDIT-C, Alcohol Use and Disorders Identification Test C; BMI, body mass index; CLDQ, Chronic Liver Disease Questionnaire; FFQ-SF, Food Frequency Questionnaire-Short Form; GGT, gamma-glutamyl transferase; HATS, HIV adherence treatment scale; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HRQoL, health-related quality of life; IPAQ-SF, International Physical Activity Questionnaire-Short Form; PROs, patient reported outcomes; SF-36, Short Form-36.

Transient elastography and serum fibrosis biomarkers

Transient elastography examination will be performed on a 6-hour fasting participant who has been informed to avoid strenuous exercise prior to testing. Four certified operators (>100 examinations before the study), one per site, blinded to clinical and biological data, will perform 10 valid acquisitions of LSM and then the software of Fibroscan will calculate the median value.²¹ The standard M probe will be used in all patients. The XL probe will be used in patients with BMI>30 kg/m² and in case of failure of Fibroscan examination by the M probe. The following manufacturer recommendations will be applied to define the result of Fibroscan as reliable: 10 validated measures, IQR<30% of the median.³¹ Presence of significant liver fibrosis and ACLD will be defined as LSM>7.1 kPa and

LSM>10 kPa, respectively.^{9 32} CAP measurement will be performed simultaneously to assess liver steatosis.³³ The following decisional cut-offs will be applied: no MASLD (CAP<285 dB/m), mild MASLD (CAP 285–300 dB/m) and severe MASLD (CAP>300 dB/m).²⁸ We will also compute the serum fibrosis biomarkers AST-to-Platelet Ratio index and fibrosis-4 index, as previously described in PWH.³⁴

Questionnaires

Self-assessment questionnaires will be completed by participants at each visit to collect:

- ▶ Medical, sociodemographic and lifestyle information: AUDIT-C³⁵; eating habits assessed by the Food Frequency Questionnaire-Short Form³⁶; physical activity assessed by the International Physical Activity Questionnaire-Short Form^{37 38}; substance use behaviour; smoking habits; tea and coffee use; HIV adherence treatment scale.
- ▶ Patient reported outcomes and HRQoL: CLDQ and SF-36. The CLDQ is a validated liver disease specific quality of life index consisting of 29 items divided into six subscales and correlated with the severity of liver disease.³⁹ Scores on the six subscales range from 1 to 7. An overall CLDQ score is then calculated (range=1–7). Higher scores on each CLDQ scale reflect better HRQoL.⁴⁰ The SF-36 consists of 36 questions that make up eight subscales.⁴¹ Within each dimension, 0 is the worst and 100 is the best possible score. An overall SF-36 score is then calculated, with a score greater or less than 50 representing better or poorer health than the general population, respectively.⁴¹
- ▶ Healthcare resource usage: report of number of visits to family medicine doctors, specialists, emergency rooms.

Participants who require help with reading and writing will be assisted by the study coordinators.




Figure 1 Sample size estimation. MASLD, metabolic dysfunction-associated steatotic liver disease.

Laboratory test review

The results of the blood tests obtained for clinical evaluations at each visit as per routine standard of care will be reviewed. Routine haematology, chemistry and serological evaluations will include: liver function tests (alanine transaminase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, total bilirubin, albumin, coagulation profile); complete blood count; biochemistry (fasting lipid profile, glucose, insulin and glycosylated haemoglobin, renal function tests); autoimmune markers (autoantibodies, immunoglobulins); serum ferritin and transferrin saturation; hepatitis A, B and C serology; HIV-related variables (plasma HIV RNA, absolute and relative CD4, nadir CD4, CD8 T-cell counts, CD4/CD8 ratio).

Biobanking samples

Due to infrastructure constraints, biobanking samples will take place at the MUHC. Only plasma and serum from blood will be collected, and it will be stored for as long as the bank has a scientific interest to the community and the research team can ensure its management. To avoid multiple blood draws and visits, blood collection will be scheduled during routine clinical blood draw.

Statistical analyses

Primary analysis

Specific aim 1: determine the incidence of ACLD according to MASLD status

The cumulative incidence of ACLD (primary outcome) will be calculated using the Kaplan-Meier survival method, comparing individuals with versus without MASLD, as assigned at baseline. A propensity score method will be applied to account for imbalances in the covariate distributions between participants with and without MASLD at baseline using inverse probability weighting (IPW).^{42 43} Next, to account for the time-varying nature of the exposure and confounders, we will use a multinomial logistic model using time-varying covariates to calculate IPW for the categorical exposure (MASLD) to represent escalating severity of the disease. Marginal structural models with stabilised IPW weights will be calculated at each follow-up visit. We will use an absolute standardised mean difference of 0.1 as a cut-off. We hypothesise a dose-response of our exposure, meaning increased liver fat increases the risk of ACLD. Liver fat will be evaluated in three levels: no MASLD (CAP<285 dB/m); mild MASLD (CAP 285–300 dB/m) and severe MASLD (CAP>300 dB/m). To account for baseline liver fibrosis severity measured by transient elastography, we will also conduct a stratified analysis of the incidence of ACLD according to the baseline presence of significant liver fibrosis.

Specific aim 2: develop a risk score to predict development of ACLD

The full cohort will be divided into a training set (to develop the risk score) and a validation set to internally validate the score. Associations of predictors with ACLD will be analysed using Cox proportional hazards

regression. Weights will be assigned for each predictor and the risk score will be computed as a linear combination of the weighted predictors.^{44 45} The 5-year risk of ACLD will be calculated by inserting the individual risk score into the survivor function from the proportional hazards model: $P(\text{ACLD}, 5y)_i = 1 - S_M(5y)^{\exp(RS_i - RS_m)}$ where S_M =survivor function estimate at 5 years and at means of all predictors, RS_i =individual risk score estimated as the linear combination of weighted predictors and RS_m =risk score estimated at means of all predictors. Departure from the proportional hazards assumption will be evaluated for all predictors based on Schoenfeld residuals. Apart from the full model defined a priori, we will fit a reduced model consisting of those predictors that were significantly related to ACLD in the full model and will test for possible interactions between various predictor variables (particularly by biological sex).⁴⁶ Model performance will be evaluated by means of discrimination and calibration.⁴⁷ Discrimination is described by the c index for survival analysis, which quantifies the model's ability to separate persons with longer event-free survival from those with shorter event-free survival. In addition, we will compute the continuous net reclassification improvement (NRI) to compare the discriminatory ability of the different models. NRI values above 0.6 are considered strong, and values below 0.2, weak. For the category-based NRI, we will use three clinically relevant risk categories: low risk, <10%; medium risk, >10%–25% and high risk, >25%.⁴⁸ The categories are determined based on estimates of mortality from liver disease in those with chronic HCV infection from published reports, as well as opinions of knowledgeable hepatologists and clinicians.^{49 50} Calibration measures how well predicted probabilities agree with observed risks. We will present plots comparing observed proportions of events (from the validation sample) against average predicted probabilities across tenths of predicted risk. We will calculate sensitivity, specificity, positive predictive value and negative predictive value for a range of potential cut-off points to define high-risk individuals. To find the optimal cut-off point, we will use the Youden index (J), defined as $J = \text{sensitivity} + \text{specificity} - 1$.⁵¹ It allows finding the threshold for which sensitivity and specificity are maximised.

Secondary analysis

HRQoL scores and healthcare resource usage will be compared by MASLD status using generalised linear mixed effects model. Negative binomial regression analyses will also be used to ascertain how diagnosis relates to the HRQoL domains and to healthcare resource usage, controlling for sex, ethnicity, BMI, Fibroscan score, diabetes and HIV-related variables (ART regimens, HIV viral load, CD4 cell count, nadir CD4).

ETHICS AND DISSEMINATION

Ethics

This study will be conducted in accordance with the Canadian Tri-Council Policy Statement Version 2 and

the principles in the Declaration of Helsinki. Written informed consent will be obtained from all study participants. Patients at the MUHC will be invited to participate into the biobank substudy. Participants who decline consent for biobanking study will be allowed to participate in the cohort study only. At the time of initial manuscript submission (June 2023), the protocol of the LIVEHIV Cohort has been approved by the ethics committees of all participating institutions: (1) MUHC Research Ethics Board (REB), (2) Ottawa Health Science Network REB, (3) University Health Network REB, (4) the Oak Valley Health REB. Patient enrolment for this trial began in January 2022 at the MUHC, and it will begin in July 2023 at the other sites. Both the protocol and informed consent forms were reviewed and approved by the CTN Community Advisory Committee.

Availability of data and materials

All participant-related information will be kept confidential. All records will be kept in a secure, locked location only accessible to research staff. Participants will be identified only by a coded number specific to each participant. All computerised databases will identify participants by numeric codes only and will be password protected. On request, and in the presence of the investigator or his/her representative, participant records will be made available to the study sponsor, monitoring groups representative of the study sponsor, representatives of funding groups, and applicable regulatory agencies for the purpose of verification of clinical study procedures and/or data, as is permissible by local regulations.

Dissemination

We will share research findings to the broader research communities by scientific and lay publications and through presentations at scientific conferences and community-based HIV clinics. A knowledge translation working group will systematically synthesise the findings of this study and tailor knowledge for identified stakeholders (decision makers, clinicians, PWH and their advocates).

Patient and public involvement

Our team is committed to integrated knowledge translation by involving community members and PWH in the design and interpretation of the analysis, with two of the CTN coapplicants and coauthors (CP and KM) being community member leaders in dissemination and advocacy for PWH. Community members were engaged in evaluating the research questions of this study, which were considered high priorities for PWH.

DISCUSSION

Herein, we present the protocol for a multicentre observational cohort study designed to evaluate the role of MASLD in the development of ACLD in PWH and to develop a risk score to classify PWH according to their




Figure 2 Hypothetical pathogenesis of advanced chronic liver disease in HIV mono-infection. ACLD, advanced chronic liver disease; ART, antiretroviral therapy; LIVEHIV, LIVER disease in HIV; MASLD, metabolic dysfunction-associated steatotic liver disease.

risk of incident ACLD. This study will also investigate the impact of MASLD on HRQoL and healthcare resource usage in PWH. The results of this study will be of immediate importance since PWH face inequities and disadvantages as they are currently excluded from global clinical trials of new MASLD-targeted therapies able to halt the progression to ACLD and from case-finding strategies in MASLD.^{25 26}

Whether MASLD is a key player or a mere bystander of ACLD in HIV mono-infection is still a matter of debate.^{52 53} This knowledge gap is likely due to the complexity of factors that influence the development of both MASLD and ACLD. Indeed, many factors contribute to the complex pathogenesis of ACLD in PWH (figure 2). On one hand, metabolic disorders are increasing in PWH and contribute to the growing prevalence of MASLD.^{20 54} Diabetes is four times more prevalent in HIV-positive vs HIV-negative men.⁵⁵ Dyslipidaemia and hypertension are also very common.^{4 56} In this protocol, metabolic aspects related to MASLD and ACLD are carefully considered, with markers of insulin resistance, lipid profile, anthropometric measures and concomitant antidiabetic drugs collected and scheduled for analysis. We will also develop a risk score including metabolic parameters to predict which PWH are at high risk of ACLD. On the other hand, unique risk factors may also contribute to ACLD in PWH mono-infection, who represent 86%–89% of PWH.¹⁰ First, the lifelong use of ART may result in liver fibrosis and oxidative stress in hepatocytes.^{57 58} Earlier nucleoside reverse transcriptase inhibitors, particularly d-drugs that are known to induce mitochondrial damage and impaired fatty acid oxidation in the hepatocytes, may have had a detrimental effect that could be realised as the population ages with HIV.⁵⁹ Ritonavir-boosted protease inhibitors can lead to direct liver cell stress.⁶⁰ Integrase strand transfer inhibitors (INSTI) and tenofovir alafenamide

(TAF) may cause weight gain, although the metabolic and hepatic consequences of these newer agents is unknown, with one study suggesting INSTI and TAF as independent predictors of incident hepatic steatosis,⁶¹ and others reporting reduced or no changes in liver fat after INSTI switching.^{62–64} Longer observational studies are warranted to assess the effect of INSTI on the incidence of MASLD in PWH. Second, HIV viraemia from ART treatment interruptions is a risk factor for ACLD, as HIV itself may have pro-apoptotic effects on hepatocytes.⁵⁷ Given this complexity, we may find that exposure to ART, rather than MASLD, is the major contributor to the development of ACLD in HIV mono-infected patients. Should this be the case, our findings will still provide crucial information for subsequent monitoring and screening strategies for ACLD in PWH. Our prognostic score for development of ACLD will be modelled accordingly, by weighing on exposure to ART rather than MASLD. Furthermore, our findings in Canada can serve as a model for other/different HIV realities, such as low/middle-income countries, where ART is becoming widespread, resulting in an ageing HIV-infected population and an increase in non-communicable diseases.

Although we will make careful ascertainment of covariates to control for potential confounders, and will employ sophisticated analysis to minimise biases, some issues may nevertheless arise.

- We may encounter slower recruitment rate or higher loss to follow-up than expected. In this case, we will consider including 1–2 other HIV care centres through our close link to CTN.
- We acknowledge the complexity of the ART exposure, and we will not be powered to tease out the effect of single ART drugs. However, we will conduct sensitivity analysis to account for cumulative ART exposure and by class, recent treatment interruptions and d-drugs exposure. Although not the primary aim, this cohort will be able to explore the effect of ART on incident ACLD, which can be used for future studies. Special attention will be given to INSTI and TAF in the sensitivity analysis, considering the current open debate on weight gain and/or their role in MASLD development and progression to ACLD in PWH.
- Our sample size will be limited to evaluate biological sex and the complexity of premenopause/postmenopause as an effect modifier; however, our cohort will remain the largest sample of women with HIV attempting to address this research question. Our data will be crucial to advocate for inclusion of women in future studies.
- We will be underpowered to assess outcomes with expected lower incidence (end-stage liver diseases) or to conduct a stratified analysis by baseline fibrosis stage. However, our study can be used to power subsequent larger-scale multicentre studies. We also plan to expand the LIVEHIV Cohort to an International Cohort through the Steatohepatitis in HIV Emerging Research Network,^{25 26 65} with the purpose of assessing

these rare outcomes, as well as validating externally the prognostic risk score.

- The lack of a histological diagnosis is a limitation. However, transient elastography provides a simultaneous point-of-care assessment of liver fat and fibrosis, and has been extensively validated in MASLD^{66 67} and in PWH.^{32 33 68} Besides, non-invasive diagnostic tools are patient-friendly, cost-effective and help broaden the study generalisability and reduce selection biases. We will also compute and follow longitudinally validated serum fibrosis biomarkers.
- Most participants will be recruited from tertiary hospitals, with possible over-representation of complex cases and under-representation of marginalised patients, such as indigenous people. However, we will attempt to broaden generalisability by promoting the study through community partners and the CTN via websites, email and social media.

In conclusion, our findings will demonstrate that HIV is a convergence for two epidemics, ACLD and MASLD, thereby generating evidence to advocate for equity and inclusion of PWH in global trials of new antifibrotic molecules for MASLD and case-finding of PWH at high risk of developing ACLD. Overall, we expect that our results will change clinical practice, policies and improve healthcare outcomes for PWH.

Author affiliations

¹Chronic Viral Illness Service, McGill University Health Centre, Montreal, Quebec, Canada

²Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada

³Public Health Sciences, Queen's University, Kingston, Ontario, Canada

⁴Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada

⁵Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada

⁶Canadian HIV/AIDS and Chronic Pain Society, Ottawa, Ontario, Canada

⁷COCQ SIDA, Montreal, Quebec, Canada

⁸Department of Medicine, Division of Infectious Diseases, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

⁹Department of Medicine, Division of Infectious Diseases, University of Toronto, Toronto, Ontario, Canada

¹⁰Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada

¹¹Chronic Viral Illness Service, McGill University, Montreal, Quebec, Canada

¹²Department of Family Medicine, McGill University Faculty of Medicine and Health Sciences, Montreal, Quebec, Canada

Twitter Wesal Elgretli @WesalElgretli and Melanie C M Murray @DrMelanieMurray

Contributors The principal investigator of the study is GS. Site investigators of the study are MBK, CTC, SLW, NP, MCM. Other CTN coapplicants are SS (Methodologist), EM (Methodologist), KM (Community Representatives), CP (Community Representatives). GS conceived the study, led the proposal and protocol development. SS and EM provided methodological expertise and performed sample size calculations. FC, DK, LRB, WE, BL, JC, NK, CTC, J-PR and AdP are involved in patient enrolment. FC, SS and GS wrote the first draft of the manuscript. MNK, CTC, SLW, EEMM, NP, MCM, DK, LRB, WE, JC, BL, NK, CTC, J-PR and AdP reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding The study was funded by an operating grant from the Canadian Institute of Health Research (CIHR) and by the CIHR Canadian HIV Trials Network. WE has received PhD fellowship from the Canadian Network on Hepatitis C (CanHepC). CanHepC is funded by a joint initiative of the Canadian Institutes of Health Research

(NPC-178912) and the Public Health Agency of Canada. SLW is the Speck Family Chair in emerging infectious diseases. NK and CTC are supported by a Fonds de Recherche du Québec-Santé (FRQS) Junior two career award. AdP is supported by a Senior Salary Award from FRQS. BL is supported by two career awards: a Senior Salary Award from Fonds de recherche du Québec-Santé (FRQS) (#311200) and the LE 250 (from the Québec Ministry of Health for researchers in Family Medicine), from the Québec's Ministry of Health for researchers in Family Medicine and holds a Canadian Institutes for Health Research, Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical Trials for HIV Care. J-PR is the holder of the Louis Lowenstein Chair in Haematology and Oncology, McGill University. GS is supported by a Senior Salary Award from FRQS (#296306).

Competing interests BL has acted as a speaker and advisory board member for ViiV, Gilead and Merck, and received research funding from ViiV, Merck and Gilead. CTC has received research funding from Merck, Gilead and Tilray, speaker honorarium from Gilead and consultant fees from ViiV Healthcare and Moderna. She has received funding to attend conferences from Gilead and ViiV Healthcare, and cannabinoids from Tilray for use in a clinical trial. SLW has served on advisory board, and spoken at CME event for Merck, Gilead, ViiV, and has received research funds from ViiV, Gilead and Merck. JC has received funding for investigator-initiated research from ViiV Healthcare and remuneration for advisory work from Gilead Canada and ViiV Healthcare. MCMM has served on advisory boards and spoken at CME events for Merck, Gilead and ViiV, and has received research funds from ViiV. GS has acted as speaker for Merck, Gilead, Abbvie, NovoNordisk, Pfizer, served as an advisory board member for Pfizer, Merck, NovoNordisk, Gilead and Intercept and has received unrestricted research funding from Theratechnologies. FC, SS, DK, LRB, WE, EEMM, CP, KM, NP, NK, AdP, J-PR, MBK have no conflict of interests.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Felice Cinque <http://orcid.org/0000-0003-1499-9233>

Curtis Cooper <http://orcid.org/0000-0002-3368-3499>

Cecilia T Costiniuk <http://orcid.org/0000-0002-4547-714X>

Alexandra de Pokomandy <http://orcid.org/0000-0001-6809-1357>

Jean-Pierre Routy <http://orcid.org/0000-0001-9897-7589>

Bertrand Lebouché <http://orcid.org/0000-0002-1273-9393>

Giada Sebastiani <http://orcid.org/0000-0003-2655-8283>

REFERENCES

- 1 Canada PHA. Estimates of HIV incidence, prevalence and Canada's progress on meeting the 90-90-90 HIV targets. 2020. Available: <https://www.canada.ca/en/public-health/services/publications/diseases-conditions/estimates-hiv-incidence-prevalence-canada-meeting-90-90-90-targets-2020.html> [Accessed 15 May 2023].
- 2 Global HIV & AIDS Statistics — fact sheet. Available: <https://www.unaids.org/en/resources/fact-sheet> [Accessed 15 May 2023].
- 3 Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. *N Engl J Med* 1998;338:853-60.
- 4 Guaraldi G, Lonardo A, Maia L, et al. Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver. *AIDS* 2017;31 Suppl 2:S147-56.
- 5 Rosenthal E, Salmon-Céron D, Lewden C, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC joint study group network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS En19). *HIV Med* 2009;10:282-9.
- 6 Croxford S, Kitching A, Desai S, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. *Lancet Public Health* 2017;2:e35-46.
- 7 de Franchis R. Expanding consensus in portal hypertension. *Journal of Hepatology* 2015;63:743-52.
- 8 Petta S, Sebastiani G, Viganò M, et al. Monitoring occurrence of liver-related events and survival by transient Elastography in patients with Nonalcoholic fatty liver disease and compensated advanced chronic liver disease. *Clin Gastroenterol Hepatol* 2021;19:806-15.
- 9 de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - renewing consensus in portal hypertension. *J Hepatol* 2022;76:959.
- 10 Kaspar MB, Sterling RK. Mechanisms of liver disease in patients infected with HIV. *BMJ Open Gastroenterol* 2017;4:e000166.
- 11 Paik JM, Henry L, Golabi P, et al. Presumed Nonalcoholic fatty liver disease among Medicare beneficiaries with HIV, 2006-2016. *Open Forum Infect Dis* 2020;7:ofz509.
- 12 Rinella ME, Lazarus JV, Ratzliff V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. *Hepatology* 2023;Publish Ahead of Print.
- 13 Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of Nonalcoholic fatty liver disease. *Hepatology* 2023;77:1797-835.
- 14 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016;64:1388-402.
- 15 Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): a systematic review. *Hepatology* 2023;77:1335-47.
- 16 Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for Nonalcoholic Steatohepatitis in the United States. *Gastroenterology* 2011;141:1249-53.
- 17 Byrne CD, Targher G. NAFLD: a Multisystem disease. *Journal of Hepatology* 2015;62:S47-64.
- 18 Golabi P, Otgonsuren M, Cable R, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of health related quality of life (HRQL). *Health Qual Life Outcomes* 2016;14:18.
- 19 Allen AM, Van Houten HK, Sangaralingham LR, et al. Healthcare cost and utilization in Nonalcoholic fatty liver disease: real-world data from a large US claims database. *Hepatology* 2018;68:2230-8.
- 20 Cervo A, Shengir M, Patel K, et al. NASH in HIV. *Curr HIV/AIDS Rep* 2020;17:601-14.
- 21 Vuille-Lessard É, Lebouché B, Lennox L, et al. Nonalcoholic fatty liver disease diagnosed by transient Elastography with controlled Attenuation parameter in Unselected HIV Monoinfected patients. *AIDS* 2016;30:2635-43.
- 22 Pembroke T, Deschenes M, Lebouché B, et al. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV Co-infected patients and is associated with liver fibrosis. *J Hepatol* 2017;67:801-8.
- 23 Kalligeros M, Vassilopoulos A, Shehadeh F, et al. Prevalence and characteristics of Nonalcoholic fatty liver disease and fibrosis in people living with HIV Mono-infection: A systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2023;21:1708-22.
- 24 Ryom L, De Miguel R, Cotter AG, et al. Major revision version 11.0 of the European AIDS clinical society guidelines 2021. *HIV Medicine* 2022;23:849-58. 10.1111/hiv.13268 Available: <https://onlinelibrary.wiley.com/toc/14681293/23/8>
- 25 Sebastiani G, Milic J, Tsochatzis EA, et al. Letter to the editor: people living with HIV and NAFLD: A population left behind in the global effort for liver fibrosis screening *Hepatology* 2023;Publish Ahead of Print.
- 26 Guaraldi G, Maurice JB, Marzolini C, et al. New drugs for NASH and HIV infection: great expectations for a great need. *Hepatology* 2020;71:1831-44.
- 27 Loomba R, Lim JK, Patton H, et al. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with Nonalcoholic fatty liver disease: expert review. *Gastroenterology* 2020;158:1822.
- 28 Ajmera VH, Cachay ER, Ramers CB, et al. Optimal threshold of controlled Attenuation parameter for detection of HIV-associated NAFLD with magnetic resonance imaging as the reference standard. *Clin Infect Dis* 2021;72:2124-31.
- 29 Benmassaoud A, Nitulescu R, Pembroke T, et al. Liver-related events in human immunodeficiency virus-infected persons with occult cirrhosis. *Clin Infect Dis* 2019;69:1422-30.
- 30 CTN 326: LIVEHIV cohort plus | clinical care and management (CCM). CIHR Canadian HIV trials network. Available: <https://www.hivnet.ubc.ca/study/ctn-326-livehiv-cohort-plus/> [Accessed 6 Jun 2023].
- 31 Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. *Gastroenterology* 2012;142:1293-1302.

- 32 Morse CG, McLaughlin M, Proschan M, *et al.* Transient Elastography for the detection of hepatic fibrosis in HIV-Monoinfected adults with elevated Aminotransferases on antiretroviral therapy. *AIDS* 2015;29:2297–302.
- 33 Duarte M, Tien P, Ma Y, *et al.* Controlled Attenuation parameter accurately detects liver steatosis in people with HIV. *AIDS* 2022;36:2147–52.
- 34 Mendeni M, Focà E, Gotti D, *et al.* Evaluation of liver fibrosis: Concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. *Clin Infect Dis* 2011;52:1164–73.
- 35 Bush K, Kivlahan DR, McDonnell MB, *et al.* The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. ambulatory care quality improvement project (ACQUIP). *Arch Intern Med* 1998;158:1789–95.
- 36 Cleghorn CL, Harrison RA, Ransley JK, *et al.* Can a dietary quality score derived from a short-form FFQ assess dietary quality in UK adult population surveys. *Public Health Nutr* 2016;19:2915–23.
- 37 Craig CL, Marshall AL, Sjöström M, *et al.* International physical activity questionnaire: 12-country Reliability and validity. *Med Sci Sports Exerc* 2003;35:1381–95.
- 38 Fazeli PL, Marquine MJ, Dufour C, *et al.* Physical activity is associated with better Neurocognitive and everyday functioning among older adults with HIV disease. *AIDS Behav* 2015;19:1470–7.
- 39 Younossi ZM, Stepanova M, Henry L, *et al.* A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic Steatohepatitis: CLDQ-NAFLD. *Liver Int* 2017;37:1209–18. 10.1111/liv.13391 Available: <http://doi.wiley.com/10.1111/liv.2017.37.issue-8>
- 40 Younossi ZM, Guyatt G, Kiwi M, *et al.* Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. *Gut* 1999;45:295–300.
- 41 Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. *Medical Care* 1992;30:473–83.
- 42 Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. *Stat Med* 2014;33:1242–58.
- 43 Mertens BJ, Datta S, Brand R, *et al.* Causal effect estimation strategies in a longitudinal study with complex time-varying confounders: A Tutorial. *Stat Methods Med Res* 2017;26:337–55.
- 44 Pavlou M, Ambler G, Seaman SR, *et al.* How to develop a more accurate risk prediction model when there are few events. *BMJ* 2015;351:h3868.
- 45 Ware JH. The limitations of risk factors as Prognostic tools. *N Engl J Med* 2006;355:2615–7.
- 46 Pepe MS, Feng Z, Huang Y, *et al.* Integrating the Predictiveness of a marker with its performance as a Classifier. *American Journal of Epidemiology* 2008;167:362–8.
- 47 Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. *Circulation* 2007;115:928–35.
- 48 Leening MJG, Vedder MM, Witteman JCM, *et al.* Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide. *Ann Intern Med* 2014;160:122–31.
- 49 Hallager S, Brehm Christensen P, Ladelund S, *et al.* Mortality rates in patients with chronic hepatitis C and cirrhosis compared with the general population: A Danish cohort study. *J Infect Dis* 2017;215:192–201.
- 50 van der Meer AJ, Veldt BJ, Feld JJ, *et al.* Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA* 2012;308:2584–93.
- 51 Chen F, Xue Y, Tan MT, *et al.* Efficient statistical tests to compare Youden index: accounting for contingency correlation. *Statist Med* 2015;34:1560–76. 10.1002/sim.6432 Available: <http://doi.wiley.com/10.1002/sim.v34.9>
- 52 Cai J, Sebastiani G. Elevated transaminases, fatty liver: the perfect storm *J Acquir Immune Defic Syndr* 2019;81:e23–5.
- 53 Iogna Prat L, Tsochatzis EA. Human immunodeficiency virus and fatty liver: the perfect storm or a storm in a teacup *J Acquir Immune Defic Syndr* 2019;81:e25–6.
- 54 Benmassaoud A, Ghali P, Cox J, *et al.* Screening for Nonalcoholic Steatohepatitis by using Cytokeratin 18 And transient Elastography in HIV mono-infection. *PLoS One* 2018;13:e0191985.
- 55 Brown TT. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. *Arch Intern Med* 2005;165:1179.
- 56 Sprinz E, Lazzaretti RK, Kuhmmer R, *et al.* Dyslipidemia in HIV-infected individuals. *Braz J Infect Dis* 2010;14:575–88.
- 57 Kovari H, Weber R. Influence of antiretroviral therapy on liver disease. *Current Opinion in HIV and AIDS* 2011;6:272–7.
- 58 Ingiliz P, Valantin M-A, Duvivier C, *et al.* Liver damage underlying unexplained transaminase elevation in human immunodeficiency Virus-1 mono-infected patients on antiretroviral therapy. *Hepatology* 2009;49:436–42.
- 59 Merchante N, Pérez-Camacho I, Mira JA, *et al.* Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis Coinfection: role of Didanosine. *Antivir Ther* 2010;15:753–63.
- 60 Sulkowski MS, Mehta SH, Chaisson RE, *et al.* Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent Ritonavir. *AIDS* 2004;18:2277–84.
- 61 Bischoff J, Gu W, Schwarze-Zander C, *et al.* Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). *EclinicalMedicine* 2021;40:101116.
- 62 Calza L, Colanelli V, Borderi M, *et al.* Improvement in liver steatosis after the switch from a Ritonavir-boosted protease inhibitor to Raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. *Infect Dis (Lond)* 2019;51:593–601.
- 63 Macias J, Mancebo M, Merino D, *et al.* Changes in liver steatosis after switching from Efavirenz to Raltegravir among human immunodeficiency virus-infected patients with Nonalcoholic fatty liver disease. *Clin Infect Dis* 2017;65:1012–9.
- 64 Hanttu A, Vuoti S, Kivela P, *et al.* Liver fat, Adipose tissue, and body composition changes after switching from a protease inhibitor or Efavirenz to Raltegravir. *AIDS Patient Care STDS* 2021;35:335–41.
- 65 Maurice JB, Goldin R, Hall A, *et al.* Increased body mass index and type 2 diabetes are the main predictors of Nonalcoholic fatty liver disease and advanced fibrosis in liver biopsies of patients with human immunodeficiency virus Monoinfection. *Clin Infect Dis* 2021;73:e2184–93.
- 66 Petroff D, Blank V, Newsome PN, *et al.* Assessment of hepatic steatosis by controlled Attenuation parameter using the M and XL probes: an individual patient data meta-analysis. *The Lancet Gastroenterology & Hepatology* 2021;6:185–98.
- 67 Friedrich-Rust M, Ong M-F, Martens S, *et al.* Performance of transient Elastography for the staging of liver fibrosis: a meta-analysis. *Gastroenterology* 2008;134:960–74.
- 68 Lemoine M, Assoumou L, De Wit S, *et al.* Diagnostic accuracy of noninvasive markers of steatosis, NASH, and liver fibrosis in HIV-Monoinfected individuals at risk of Nonalcoholic fatty liver disease (NAFLD): results from the ECHAM study. *J Acquir Immune Defic Syndr* 2019;80:e86–94.